Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05626634




Registration number
NCT05626634
Ethics application status
Date submitted
15/11/2022
Date registered
25/11/2022
Date last updated
23/05/2024

Titles & IDs
Public title
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Scientific title
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks
Secondary ID [1] 0 0
LP352-202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Developmental and Epileptic Encephalopathy 0 0
Dravet Syndrome 0 0
Lennox-Gastaut Syndrome 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LP352, bexicaserin

Experimental: LP352, bexicaserin - Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.


Treatment: Drugs: LP352, bexicaserin
LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Treatment-emergent Adverse Events
Timepoint [1] 0 0
Baseline up to Week 52
Primary outcome [2] 0 0
Columbia-Suicide Severity Rating Scale (C-SSRS) Response
Timepoint [2] 0 0
Baseline up to Week 52
Primary outcome [3] 0 0
Patient Health Questionnaire-9 Total Score and Question 9 Score
Timepoint [3] 0 0
Baseline up to Week 52
Secondary outcome [1] 0 0
Percent Change from Baseline in Observed Countable Motor Seizure Frequency During the Treatment Period
Timepoint [1] 0 0
Baseline to Week 50
Secondary outcome [2] 0 0
Proportion of Subjects with > 50% Reduction in Total Seizures During the Treatment Period
Timepoint [2] 0 0
Baseline to Week 50
Secondary outcome [3] 0 0
Percent Reduction in Individual Seizure Type During the Treatment Period
Timepoint [3] 0 0
Baseline to Week 50
Secondary outcome [4] 0 0
Proportion of Subjects Requiring Rescue Medication During the Treatment Period
Timepoint [4] 0 0
Baseline to Week 50
Secondary outcome [5] 0 0
Percent Change from Baseline in the Number of Episodes of Status Epilepticus During the Treatment Period
Timepoint [5] 0 0
Baseline to Week 50
Secondary outcome [6] 0 0
Percent of Subjects with Countable Motor Seizure-free Days During the Treatment Period
Timepoint [6] 0 0
Baseline to Week 50
Secondary outcome [7] 0 0
Percentage Change from Baseline in Non-motor and Difficult to Count Seizures
Timepoint [7] 0 0
Baseline to Week 50
Secondary outcome [8] 0 0
LGS: Percentage Change from Baseline in the Frequency of Observed Drop Seizures Over the Treatment Period
Timepoint [8] 0 0
Baseline to Week 50

Eligibility
Key inclusion criteria
1. Male or non-pregnant, non-lactating female, age 12 to 65 years who have satisfactorily
completed study LP352-201

2. Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and
epileptic encephalopathy

3. The patient/parent/caregiver is able and willing to attend study visits, complete the
diary and take study drug as instructed
Minimum age
12 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Had an SAE in Study LP352-201 that was definitely, probably, or possibly related to
exposure to study drug

2. Current or past history of cardiovascular or cerebrovascular disease, such as cardiac
valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or
abnormal blood pressure

3. Has glaucoma, renal impairment, liver disease or any other medical condition that
would affect study participation or pose a risk to the subject

4. Current or recent history of moderate or severe depression, anorexia nervosa, bulimia
or at risk of suicidal behavior

5. Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or
antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications
for weight loss

6. Positive test result on the drug screen, except tetrahydrocannabinol (THC) for
patients taking prescribed cannabidiol

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2024
Actual
Sample size
Target
50
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [2] 0 0
Austin Health - Heidelberg
Recruitment hospital [3] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
3084 - Heidelberg
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Hawaii
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Longboard Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this study is to assess the long-term safety, tolerability, and efficacy of
adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who
completed participation in Study LP352-201.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05626634
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Dennis J Dlugos, MD
Address 0 0
Children's Hospital of Philadelphia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries